Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Tuesday that it has dosed its first type 2 diabetes patient in a phase two clinical trial (clinicaltrials.gov, NCT04965506) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China.
The randomised, multicentre phase two clinical trial is to assess the efficacy and safety of IBI362 compared with placebo and dulaglutide in patients with type 2 diabetes in China. The main aim of the study is to assess change from baseline in HbA1c level after 20-week dosing in patients with type 2 diabetes inadequately controlled with lifestyle intervention or metformin.
The product is a synthetic long-acting mammalian oxyntomodulin analogue and is a GLP-1R and GCGR dual agonist. It uses a fatty acyl side chain to prolong the duration of action, allowing once-weekly dosing.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes